At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 84 enrolled
Drug / intervention
Travoprost 0.004% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
In Brief
A Phase 4 clinical trial evaluating Travoprost 0.004% ophthalmic solution and Bimatoprost 0.01% ophthalmic solution for Glaucoma and 2 related conditions. Completed, enrolled 84 participants.
Detailed Summary
The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ocular hypertension after 6 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension, Open-Angle Glaucoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionJun 2012
TodayJul 2026
First PostedNov 3, 2011
Enrollment StartOct 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.7 years ago
Interventions
Travoprost 0.004% ophthalmic solutiondrug
Bimatoprost 0.01% ophthalmic solutiondrug